interesting .. the news came from Fido via an alert .. not

New Post Public Reply Private Reply Replies (1) Message Board
4kids AlanC #3837
325
interesting .. the news came from Fido via an alert .. not via my email from Innovation Pharma .. (as is usually the case) .. just read the PR from Fido ..
from 4:30PM yesterday ..

just re-checked my email and still nothing in from Innovation


Innovation Pharmaceuticals Announces $7 million Milestone Funding Agreement with Aspire Capital
Corporate
$2 million Received on Signing the Agreement


BEVERLY, MA – June 28, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that it has entered into a Securities Purchase Agreement (the “Agreement”) with Aspire Capital Fund, LLC (“Aspire”). The Company received $2 million on signing the agreement selling 5,263,158 shares at price per share of $0.38 which was the closing price of the Company’s common stock on June 26, 2018. Under the Agreement the Company can receive an additional $5 million based on clinical, regulatory and business development milestones to be reached prior to September 30, 2018. The specific milestone payments are:

· $1 million upon announcement of Breakthrough Therapy Designation from the FDA for Brilacidin as a potential treatment for oral mucositis (OM).

· $2 million upon announcement of results from the recently completed Phase 2b trial of Prurisol as a potential treatment for moderate to severe chronic plaque psoriasis showing that the trial has met its primary endpoint.

· $2 million upon announcement of the Company entering into a licensing arrangement with a pharmaceutical company for any of the Company’s clinical assets that will include an initial payment to the Company of an amount in the double-digits millions of dollars.

Each of the milestone payments will be made at a purchase price based on the five-day average of the closing prices of Company’s common stock at the time of each announcement without any discount to such five-day average.

“This investment from Aspire will enable us to fund our efforts for important clinical and regulatory progress. The near-term milestones to trigger funding under the Agreement have been an ongoing main focus for the Company. Based on the previously announced Phase 2 results in oral mucositis, we feel that the meaningful reduction in the incidence of severe OM and other favorable endpoints observed in the trial provide strong support for the potential granting of Breakthrough Therapy Designation. Thus, we continue to believe Brilacidin may represent a very promising treatment option for patients subject to this debilitating and painful disease. Additionally, we eagerly await pending results from the statistical analysis of the completed Prurisol Phase 2b trial and look forward to progress in shifting to oral dosing of Kevetrin since demonstrating positive modulation of p53 directly in ovarian cancer,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer of Innovation Pharmaceuticals.

“Aspire Capital has been a longtime shareholder and supporter of Innovation Pharmaceuticals. We are very pleased to provide the Company with additional financial support and flexibility as they approach several potentially transformational, near-term milestones,” said Steven G. Martin, Managing Member of Aspire Capital. “We believe the Company has a significant chance to achieve each of these milestones.”

Under the Agreement, the Company has also issued to Aspire Capital 2,736,842 shares and warrants to purchase an additional 8 million shares of the Company’s common stock at a price of $0.38 as fee for its commitment to make the additional milestone payments.

For additional information about the Milestone Based Purchase Agreement with Aspire Capital, refer to the current report on Form 8-K filed on June 28, 2018 with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

=========

http://www.ipharminc.com/press-release/2018/6...re-capital


=========

http://www.ipharminc.com/financials/


$5,000,000 of Class A Common Stock and Warrants

plus 8,000,000 shares of Class A Common Stock and Warrants to purchase 8,000,000 shares of Class A Common Stock

_________________________



Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 5,263,158 shares of our A common stock, which we refer to as our common stock, at $0.38 per share (the “initial purchase shares”), and up to an additional $5.0 million aggregate amount of our securities, consisting of common stock or five-year warrants to purchase shares of our common stock at an exercise price of $0.01 per share (the “pre-funded warrants”), directly to Aspire Capital Fund, LLC (“Aspire Capital”) under a Securities Purchase Agreement entered into on June 28, 2018 (the “Purchase Agreement”). The purchase prices for the additional $5.0 million of securities will be based upon formulas set forth in the Purchase Agreement, and the sale of such securities is subject to the terms and conditions set forth in the Purchase Agreement. The securities offered also include 2,736,842 shares of common stock to be issued to Aspire Capital in consideration for entering into the Purchase Agreement (the “commitment shares”) and five-year warrants to purchase 8,000,000 shares of our common stock for $0.38 per share (the “commitment warrants” and together with the pre-funded warrants, the “warrants”). This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of the warrants. We are not paying underwriting discounts or commissions. We estimate that our total expenses of this offering will be approximately $25,000.



Our common stock is traded in the over-the-counter market and is currently quoted on the OTCQB under the symbol “IPIX.” On June 26, 2018, the last reported sale price of our common stock was $0.38 per share. The warrants will not be listed on any national securities exchange or automated quotation system.

_________________________



Investing in our securities involves a high degree of risk. You should read “Risk Factors” beginning on page S-3 of this prospectus supplement and the reports we file with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended, incorporated by reference in this prospectus supplement, to read about factors to consider before purchasing our securities.



Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.



The date of this prospectus supplement is June 28, 2018.

http://www.edgarmaster.com/Inet/main/DataFeedHtml1.jsp
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring CRH Stock Performance Over Five Years and Beyond

Updated Category News Views 152

Understanding CRH's Impressive Growth CRH has displayed a remarkable performance in the stock market over the last five years, outshining many of its competitors with a 10.67% annualized return. This impressive growth translates to an average annual return of 23.49% for investors. Currently, CRH boasts a market capitalization of approximately $73.09 billion, making it a...

Continue Reading
Coordinated Care's Health Tour Expands Access Across WA

Updated Category News Views 78

A Grassroots Push for Health Equity Coordinated Care, a subsidiary of Centene Corporation, is hitting the road in Washington state. This isn't about just another healthcare campaign—you’ve got two vans, 'SeeMore' and 'Flossy', bringing essential vision and dental screenings right up to the folks who need them most. Taking Healthcare Directly to Communities Let's be...

Continue Reading
Italy's Antitrust Agency Investigates Snam-Edison Deal

Updated Category News Views 229

Investigation into the Snam and Edison Gas Storage Deal Italy's antitrust agency has recently initiated an investigation concerning the transaction between Snam and Edison involving Edison's gas storage unit. This move reflects the agency's commitment to maintaining healthy competition within the energy sector. Concerns Over Market Competition The Antitrust Authority,...

Continue Reading
Truist Financial Corporation's Quarterly Performance Insights

Updated Category News Views 240

Truist Financial's Results and Earnings Overview Truist Financial Corporation (TFC) announced its latest quarterly results, showcasing a robust financial performance that illustrates the company’s strategic focus on growth and stability. This release reflects the commitment of Truist to enhance the lives of its clients and communities by providing comprehensive...

Continue Reading
Investigation Into Possible Securities Fraud at UnitedHealth Group

Updated Category News Views 350

UnitedHealth Group Under Scrutiny for Securities Claims Ademi & Fruchter LLP has launched an investigation into potential securities fraud claims against UnitedHealth Group Incorporated (NYSE: UNH). This inquiry arises following inaccurate statements made by the company regarding its operational performance and future outlook. Investors and analysts alike express serious...

Continue Reading